Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;12(5):E197-E209.
doi: 10.5489/cuaj.5255. Epub 2018 Feb 22.

2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature

Anthony J Bella  1 , Jay C Lee  2 , Ethan D Grober  3 , Serge Carrier  4 , Francois Benard  5 , Gerald B Brock  6
Affiliations

2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature

Anthony J Bella et al. Can Urol Assoc J. 2018 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Bella has been a consultant for Paladin Labs; an investigator for Boston Scientific; and co-founded and was co-principal investigator for the PROPPER Registry Study (PROPPER Prospective Registry of Outcomes With Penile Prosthesis) (ClinicalTrials.gov Identifier: NCT01383018). Dr. Lee has attended advisory board for Acerus and Paladin; is a speaker for Acerus, Astellas, and Paladin; has received honoraria from Acerus, Astellas, Paladin, and Pfizer; and has participated in clinical trials supported by Acerus. Dr. Grober has attended advisory boards for Paladin; has been a consultant for Acerus, Apotex, and Mylan; has been a speaker for Acerus and Mylan; and holds shares in MHB Labs. Dr. Carrier has attended advisory boards for Acerus, Astellas, Boston Scientific, Paladin/Endo, Pfizer, Repros Medical, and Sanofi; has been a speaker for Duchesnay and Janssen; and has participated in clinical trials supported by Astellas. Dr. Brock has attended advisory boards for Boston Scientific, Eli Lilly, and Paladin; has been a speaker for Astellas, Eli Lilly, Ferring, and Pfizer; hold investments in Eli Lilly and Pfizer; and has participated in clinical trials supported by Astellas and Ferring.

Figures

Fig. 1
Fig. 1
Treatment algorithm. ED: erectile dysfunction; NSAID: non-steroidal anti-inflammatory drug; PDE5I: phosphodiesterase type 5 inhibitor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chung E, Ralph D, Kadioglu A, et al. Evidence-based management guidelines on Peyronie’s Disease. J Sex Med. 2016;13:905–23. https://doi.org/10.1016/j.jsxm.2016.04.062. - DOI - PubMed
    1. Dahm P, Jung JH, Bodie J. Moving from consensus- to evidence-based clinical practice guidelines for Peyronie’s disease. J Sex Med. 2017;14:170–1. https://doi.org/10.1016/j.jsxm.2016.10.015. - DOI - PubMed
    1. Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745–53. https://doi.org/10.1016/j.juro.2015.05.098. - DOI - PMC - PubMed
    1. Bella AJ, Greenfield JM. In: Peyronie’s Disease: Epidemiology, Pathophysiology and Evaluation. Chile KA, editor. AUA Core Curriculum, American Urological Association Education and Research Inc.; 2016. [Accessed July 30 2017]. https://university.auanet.org/core_topic.cfm?coreid=103.
    1. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175:2115–8. https://doi.org/10.1016/S0022-5347(06)00270-9. - DOI - PubMed

LinkOut - more resources